# Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

> **NCT05770882** · PHASE1,PHASE2 · TERMINATED · sponsor: **Great Novel Therapeutics Biotech & Medicals Corporation** · enrollment: 7 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT05770882
- **Lead sponsor:** Great Novel Therapeutics Biotech & Medicals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-25
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The overall profile does not support development for Hepatocellular Carcinoma
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05770882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05770882, "Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05770882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*